MGX vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MGX exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company suffers from a catastrophic negative gross margin (-274.58%) and a significant decline in year-over-year revenue (-59.30%), suggesting a failing or highly inefficient business model. While the current ratio of 7.22 provides a temporary liquidity cushion, the combination of bearish insider selling by the CEO and CFO and a 0/100 technical trend suggests a lack of confidence in near-term recovery. Despite a high analyst target price of $9.33, the deterministic data points to a high-risk speculative asset in a downward spiral.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
MGX vs MRK: Head-to-Head Comparison
This page compares Metagenomi Therapeutics, Inc. (MGX) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.